Hepatitis C Star Drug Patent Withstands Invalidity Challenge

WISECODE Take

This news reveals that even "star drug" patents face severe challenges from competitors; patent validity is never a given. In sports, a champion's strength is not just in winning, but in consistently fending off challengers. Gilead Sciences' Hepatitis C star drug patent, "Nucleotide Aminophosphonate Prodrug" (Patent No.: ZL200880018024.2), facing an invalidity request from Beijing Kaian Technology Co., Ltd., was akin to a title defense. China National Intellectual Property Administration's Reexamination and Invalidation Department's Decision No. 588818 upheld the patent's validity, securing the original drug manufacturer's leading position. For business owners, this "patent offense and defense battle" highlights that patent strategy needs both breadth and defensive depth. Especially for chemical patents, the precision in drafting claims, such as defining stereoconfigurations in chiral compounds, directly impacts patent stability and resilience against invalidity challenges. First, during initial patent application, companies must invest in high-quality drafting to ensure claims cover all technical variants and allow for future defense. Second, when entering the market or facing competition, regularly conduct "validity assessments" of your own and competitors' patent portfolios to identify potential risks or opportunities early. "In the patent arena, only those strong in both offense and defense can remain undefeated." Zhidian can assist your enterprise with patent portfolio health checks, ensuring the robust protection of your core technologies.